Medicine & Life Sciences
Peru
100%
Cost-Benefit Analysis
69%
Costs and Cost Analysis
35%
entecavir
28%
Tenofovir
25%
Pneumococcal Vaccines
24%
Conjugate Vaccines
24%
Gross Domestic Product
24%
Treatment Adherence and Compliance
22%
Chronic Hepatitis B
21%
Pneumonia
20%
Interferons
18%
Multiple Sclerosis
17%
Antiviral Agents
17%
ceftazidime drug combination avibactam
16%
Tornadoes
16%
Quality-Adjusted Life Years
16%
Cetuximab
12%
Health
12%
Carbapenems
11%
Public Hospitals
11%
Vaccines
10%
Therapeutics
10%
Pneumococcal Pneumonia
9%
Colonic Neoplasms
9%
Myocardial Ischemia
8%
Child
8%
Colistin
8%
Patient Care
7%
Economic Models
7%
Hospitalization
7%
Bacteria
6%
Drug Therapy
5%
10-valent pneumococcal conjugate vaccine
5%
Health Care Costs
5%
Enterobacteriaceae
5%
Bacteremia
5%
Business & Economics
Cost-effectiveness
56%
Peru
41%
Multiple Sclerosis
33%
Therapy
22%
Adherence
20%
Chemotherapy
15%
Quality-adjusted Life Years
13%
Cancer
11%
Infection
11%
Gross Domestic Product
11%
Pneumonia
10%
Bacteria
10%
Incremental Cost
8%
Health State
6%
Tumor
5%
Markov Model
5%
Payment
5%
Shrinkage
5%
Social Sciences
Peru
31%
contagious disease
19%
costs
11%
Health sector
10%
willingness to pay
10%
human resources
6%
insurance coverage
6%
reform
5%
ministry
5%
public health
5%
life years
5%
health
5%
health insurance
5%